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Evidence from research is needed to justify changes in prac-
tice and is a driving force behind improvements in patient care. 
Pathology can be involved throughout the research pathway - 
from developing research ideas, designing, setting up and running 
research studies, to analysing samples, interpreting the data and 
publishing the results (Figure 1).
In addition to research initiated by pathologists, a large 
amount of research is led by researchers from outside pathol-
ogy requiring services delivered by pathology departments. 
This research often requires services delivered by pathology 
departments. For some pathology staff this service delivery, 
for example the release of material from hospital archives, 
may be their only experience of research. Data generated from 
pathology departments support research in a wide variety of 
ways. This could be informing study eligibility assessments, 
companion diagnostics, pharmacokinetics, surrogate or other 
endpoints or the provision of data, results or tissue for further 
assessment. Results may already be in the health record as 
part of routine care or they may require further analysis or 
the release of tissue to central laboratories for a standardised 
assessment.
As well as the increase in the overall workload of pathology 
departments, there have been increases in clinical trials requir-
ing pathology input. As research needs to be carried out in 
accordance with the appropriate regulatory requirements and 
standards, pathology departments need to have risk-based and 
pragmatic procedures in place to manage these requests. 
Regulations change and so it is important that pathology 




In the NHS research should be carried out in accordance with 
the UK Policy Framework for Health and Social Care Research1, 
which replaced the Department of Health Research Govern-
ance Framework in October 2017. The Framework sets out 
the principles of best practice for the management and con-
duct of all health and social care research in the UK, to help 
organisations meet their legal requirements. It covers research 
in the NHS and other health and social care environments 
across all four nations. The Framework includes fifteen prin-
ciples that apply to all research and a further four that apply 
only to interventional research. It provides a clear definition 
and outline of the roles and responsibilities for individuals and 
organisations involved in health and social care research includ-
ing the sponsor, the funder, the research team, research sites, 
clinical research organisations and regulators. It states there 
should be clear designation of responsibility and account-
ability with clear lines of communication between all those 
involved in research.
The Framework is not a regulation - it is statutory guidance 
published in order to help organisations meet their legal obliga-
tions. It is a common set of principles that apply to any study. 
Though they aren’t identical, these will be recognisable to those 
already familiar with the principles of Good Clinical Prac-
tice. The framework is an important document for all those 
involved in NHS research as it provides a common language 
for research and enhances the possibilities for a unified and 
streamlined approach to research delivery.
Figure 1. Involvement of pathology along the research study pathway. The pathology laboratory has different potential functions along 
the study pathway. Pathologists may be leading the Research Generation (green), e.g. coming up with the research question, applying for 
funding, writing up the research or providing pathology expertise to these activities as part of a multidisciplinary team. Pathologists may also 
be responsible for providing supporting Research Delivery activities (blue) for studies from outside researchers, e.g. assessing research 
protocols for local delivery and providing service activities such as reporting on or arranging the release of diagnostic tissue to research 
centres.
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Good Clinical Practice, the UK Clinical Trials 
Regulations and the MHRA
The International Council for Harmonisation (ICH) of Techni-
cal Requirements for Pharmaceuticals for Human Use Good 
Clinical Practice (GCP) is an international standard for the 
design, conduct, performance, monitoring, auditing, recording, 
analysis, and reporting of clinical trials. These internation-
ally recognised standards followed on from the Nuremberg 
Code and originate from the World Medical Association 
Declaration of Helsinki 1964 and were an attempt to overcome 
international inconsistencies in GCP2.
The Guideline for Good Clinical Practice E6 from the 
European Medicines Agency includes the 13 Principles of ICH 
GCP3. These guidelines refer to ‘clinical trials’ but may also be 
applied to other clinical investigations that may have an impact 
on the safety and well-being of human participants.
ICH GCP was incorporated into EU Directives 2001/20/EC 
and 2005/28/EC aimed at harmonising the regulation of Clini-
cal Trials in the EU4,5. These were transposed into UK Law 
via The Medicines for Human Use (Clinical Trials) Regula-
tions in 20046 revised in 20067 and have since been further 
amended. The UK has adopted the principles of GCP, but an 
additional principle relating to sponsor indemnity was added. 
This did not define ICH GCP as the legal standard unlike other 
European countries. As with the UK Policy Framework for 
Health and Social Care Research these regulations also include 
definitions and roles and responsibilities for research.
The Clinical Trial regulations define a clinical trial of an 
investigational medicinal product (CTIMP) as any investiga-
tion in human subjects, other than a non-interventional trial, 
intended (a) to discover or verify the clinical, pharmacologi-
cal or other pharmacodynamic effects of one or more medicinal 
products, (b) to identify any adverse reactions to one or more 
such products, or (c) to study absorption, distribution, metabo-
lism and excretion of one or more such products, with the 
object of ascertaining the safety or efficacy of those products. 
The Medicines and Healthcare products Regulatory Agency 
(MHRA) provide a tool for whether research is a CTIMP8 and can 
provide further assistance if required.
The regulations have had subsequent amendments in response 
to developments in healthcare, for example research interven-
tions in pandemic disease and advanced therapies such as gene 
therapy and tissue engineering. Europe will be implementing 
a new Clinical Trial Regulation (536/2014)9 during 2020 and 
this may be implemented in the UK dependent on Brexit 
negotiations and future agreements. If the new Regulation does 
not come into force during the implementation period, the 
Government has confirmed that UK law will remain aligned 
with parts of the EU’s CTR legislation that are within the UK’s 
control, in order that researchers conducting clinical trials 
can plan with greater certainty10.
The Medicines for Human Use Regulations permit inspection 
of clinical trials and their conduct, including work undertaken 
in a laboratory, by the MHRA GCP Inspectorate. It is there-
fore prudent for a laboratory to know which trials they support 
are CTIMPs and so are subject to these regulations and potential 
inspection.
The primary reference for describing the requirements of GCP 
in the context of laboratories is the EMA Reflection Paper 
for Laboratories that Perform the Analysis or Evaluation of 
Clinical Trial Samples published in 201211. This was devel-
oped based on the MHRA Guidance on the Maintenance of 
Regulatory Compliance in Laboratories that Perform the 
Analysis or Evaluation of Clinical Trial Samples (published 
in 2009 now withdrawn). This document describes expec-
tations for laboratories involved in the analysis of samples 
originating from a CTIMP.
The primary focus of inspection by the MHRA GCP Inspec-
torate is the analysis of samples that support primary and sec-
ondary endpoints and objectives of the trial. Although routine 
sample analyses for safety testing within clinical chemistry and 
haemotology laboratories are not the central focus of this inspec-
tion programme, the legislation does not differentiate between 
the purpose of different types of sample analysis; this is a prag-
matic approach by the MHRA Inspectorate and potentially any 
aspects may be reviewed during an inspection. It is expected that 
laboratories consider and implement the guidance to support all 
forms of sample analysis linked to clinical trials whilst ensuring 
that this is appropriate and proportionate for the work being 
undertaken.
Further information in relation to the conduct of clinical trials 
can be found in the Good Clinical Practice Guide (otherwise 
known as the “Grey Guide”) produced by the MHRA12. This 
covers all aspects of GCP and is a recommended reference for 
laboratories involved in clinical research (including those not 
involved in primary and secondary endpoint analysis). The 
MHRA also continues to publish blogs on a variety of top-




The Human Tissue Act (2004) relates to the removal, stor-
age and use of ‘relevant material’ for Scheduled Purposes14. 
The Act makes consent the fundamental principle to the use 
of human tissue. Although there are caveats, relevant material 
generally refers to samples, other than gametes, which include 
intact human cells. This includes most types of samples held in 
histology departments. Samples rendered acellular are not 
considered to be relevant material. There are eleven Scheduled 
Purposes for which consent is required, including ‘Research in 
connection with disorders, or the functioning, of the human 
body’. Samples collected as part of routine clinical care are not 
covered by the Human Tissue Act though they could subse-
quently be used for a Scheduled Purpose. The Act only applies 
in England, Wales and Northern Ireland as Scotland has sepa-
rate legislation which only applies to samples collected from the 
deceased15.
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The Human Tissue Authority (HTA) was created by the Human 
Tissue Act to regulate the removal, storage and use of human 
tissue. They grant licences to establishments for a range of 
specific activities involving bodies and relevant material, 
including undertaking post-mortem examinations and storage 
of relevant material for Scheduled Purposes. HTA-licensed 
establishments include hospitals (both NHS and private), 
tissue banks, NHS blood and transfusion premises, private 
pathology services, clinical research facilities, commercial life 
sciences laboratories and universities.
Institutions handling human samples must ensure that they 
have any necessary licences for the activities carried out. The 
HTA does not license the ‘use’ of tissue for research or approve 
individual research projects or clinical trials. Neither do they 
have a role in the ethical approval of research. A research 
sector licence covers the storage of the relevant material. Storage 
of relevant material for research may be exempt from the need 
for a HTA licence if the sample is being stored according to the 
protocol of a research study approved by an NHS Research 
Ethics Committee. The HTA standards and guidance for research 
are contained within Code A: Guiding Principles and the 
fundamental principle of consent16 and Code E: Research17. 
There is a useful decision chart for whether you need a research 
licence on the HTA website (Code E Annex C).
Other regulation
The regulations and guidelines that relate to research do not 
replace the existing regulations and guidelines that govern labo-
ratory practice. All the existing professional standards and regu-
lations still apply and those that relate specifically to research 
must be applied in addition to these. Examples include ISO-
1518918, the Data Protection Act19 implementing the General 
Data Protection Directive (GDPR) (as well as being custodian 
of patient samples Pathology is also custodian of their data) and 
the Transport of Dangerous Goods regulations20. Researchers 
must be aware of, and adhere to, local NHS Trust policies and 
relevant professional standards such as those set by the Gen-
eral Medical Council (GMC), Royal College of Pathologists, 
the Institute of Biomedical Science (IBMS) and the Associa-
tion of Clinical Scientists (ACS). These professional standards 
include the need to be appropriately qualified for their job roles 
and the need to maintain continued professional development 
mirroring requirements in research regulation. Further, inter-
national trials may be subject to the scrutiny of other agencies 
such as the US Food and Drug Administration (FDA) so it is 
important to consider differing regulatory requirements depending 
on the intended use of the data.
Accreditation and research
NHS Pathology laboratories and those laboratories who are 
providing clinical services are used to what was Clinical Pathology 
Accreditation and is now Accreditation to ISO 15189 (Medical 
Laboratories - requirements for quality and competence in 
medical laboratories)18 through the United Kingdom Accredi-
tation Service (UKAS). These standards are about Quality 
Management supporting a culture and systems that can also be 
used to support the needs of research regulations and 
standards.
There are no laboratory accreditation schemes for the analy-
sis of clinical trial samples run by the MHRA. For CTIMPs, 
laboratories are required to be compliant with all relevant legis-
lation which includes working to the principles of GCP. Where 
analysis is undertaken for the purposes of patient safety during 
a CTIMP and is part of a routine repertoire of practice, UKAS 
accreditation is taken into account. The regulations permit this 
work to be inspected but often there are other activities which are 
prioritised for inspection due to the risk-based approach taken. 
Study sponsors frequently ask for the UKAS accreditation 
status of a clinical laboratory as part of their study set up process. 
However, ISO 15189 itself makes no specific mention of 
research. While the standards are complementary, laboratory 
practice also needs to quality manage areas of research practice 
not covered by ISO 15189. Examples include provision for 
the management of result reporting in CTIMP studies where 
blinding may be compromised, data integrity considerations21 
and the strict processing of trial samples according to the trial 
protocol.
Laboratories can be accredited to Good Clinical Laboratory 
Practice (GCLP) by third party providers. GCLP is a term for 
various guidance documents with their origins in a set of stand-
ards produced by the World Health Organisation (WHO) for the 
purposes of supporting safety and efficacy in international stud-
ies in developing countries22 and subsequently reproduced by a 
number of non-government organisations23. Good Laboratory 
Practice (GLP) applies to all non-clinical safety studies 
which are designed to determine the effects of a chemical 
on human health, animal health and the environment. GLP 
specifically excludes clinical experiments. Both GLP and 
GCP are statutory requirements. In contrast, adherence to 
this GCLP is not a statutory requirement and is not assessed 
during regulatory GCP laboratory inspections performed by 
organisations like the MHRA.
Conclusion
There has been an increased emphasis on the importance 
of research to the NHS. Pathology’s part in healthcare and 
research is set to become even more important with diagnos-
tics being central to the rise in genomic, personalised and strati-
fied medicine. It is important that laboratories can demonstrate 
they have oversight of the research activity undertaken in their 
department. Quality management, with clear and recognisable 
processes, record keeping (and therefore traceability) and 
good communication all support compliance with regulation 
and guidance. The regulation and guidance around research 
continues to evolve, reflecting developments in healthcare. 
It is important that pathologists remain informed about the 
regulatory requirements, standards and guidance and maintain 
their professionalism towards the research activities they are 
involved with. This paper is an overview to highlight some 
of the regulations and policies around research rather than a 
comprehensive review. Digital and molecular pathology are 
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areas of research shaping future clinical practice. Through such 
continued leadership in research, pathology is and will remain a 
central scientific discipline in clinical practice.
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